ADD-How important is the FDA approval of once weekly dosage of Kyprolis for multiple myeloma patients?

In this weeks video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients.

BOTTOM LINE:
The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and doesnt lead to additional toxicities.